LSC
CTOR

Logan Stone Capital’s Citius Oncology CTOR Stock Holding History

Logan Stone Capital’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-243,158
Closed -$2.76M – 169
2024
Q2 		$2.76M Buy
+243,158
New +$2.73M 0.71% 38

Other funds holding CTOR

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Logan Stone Capital's CTOR Position: Q3 2024 in Review

Logan Stone Capital sold out of Citius Oncology (CTOR) in Q3 2024, closing a stake of 243,158 shares — an estimated $2.76M sold.

Logan Stone Capital first reported a position in CTOR in Q2 2024 and held it in 1 quarter. The position peaked at $2.76M in Q2 2024. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2024.

  • Logan Stone Capital reported no remaining Citius Oncology position as of Q3 2024 after selling out during the quarter.
  • Logan Stone Capital sold 243,158 Citius Oncology shares in Q3 2024, an estimated $2.76M.
  • Logan Stone Capital first reported a position in Citius Oncology in Q2 2024 and held it in 1 quarter.
  • Logan Stone Capital's Citius Oncology position peaked at $2.76M in Q2 2024.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2024.

Based on Logan Stone Capital's 13F filing for Q3 2024, filed 14 Nov 2024.